Medical device manufacturer Medical Developments International (ASX:MVP) has received regulatory approval from the Health Sciences Authority in Singapore to market and sell Penthrox. MVP is the only global supplier of Penthrox, an emergency pain relief device developed in Australia and commonly known as “the green whistle”. The approval follows the recent European licence, development and commercialisation agreement that was finalised between MVP and Mundipharma International, with Mundipharma paying MVP upfront and milestone payments of up to $54.5 million US dollars. MVP shares have risen significantly in September, and closed up 9.8% for the week. We own MVP in the investment portfolio.